What type of drug does Apelix belong to? How to exert anti-cancer effect

Alpelisib (Alpelisib) is a targeted therapy drug that belongs to the PI3K inhibitor class of drugs. It is mainly used to treat specific types of breast cancer, especially HER2 span>negative, hormone receptor-positive breast cancer (HR+/HER2-), and the patient's tumor has a PIK3CA gene mutation. Apelvis exerts its anti-cancer effect by inhibiting the PI3Kα isoform in the PI3K/AKT/mTOR signaling pathway. The specific mechanism is to regulate a variety of biological processes in cells and inhibit the proliferation, survival, migration and other activities of tumor cells, thereby achieving anti-cancer effects.

PI3K (Phosphatidylinositol3kinase) is an important signaling enzyme in cells, responsible for regulating cell proliferation, differentiation, survival, migration and metabolism. In many cancers, especially breast cancer, abnormal activation of the PI3K pathway is an important driver of tumor cell proliferation and survival. Specifically, mutations in the PIK3CA gene can lead to overactivity of the PI3Kα isoform, which in turn activates downstream signaling molecules such as AKT and mTOR, promoting the disordered proliferation of tumor cells. Apelvis reduces the activity of this pathway by selectively inhibiting PI3Kα isoform, thereby inhibiting tumor growth.

Apelix’s mechanism of action is based on its highly selective inhibition ofPI3Kα isoform. PI3Kis divided into multiple subtypes, among which PI3Kα isoform plays a crucial role in various cancers, especially breast cancer. Apelvis can specifically bind to PI3Kα isoform and inhibit its catalytic activity, thereby reducing intracellular phosphatidylinositol(3,4,5)-triphosphate (PIP3) blocks the activation of the AKT/mTOR pathway, thereby inhibiting the proliferation and survival of cancer cells. Studies have shown that Apelvis can not only effectively reduce the proliferation rate of tumor cells, but also induce apoptosis of cancer cells, enhance the sensitivity of cells to anti-drug treatment, and exert an anti-tumor effect.

Apelvis is often used in combination with non-steroidal anti-estrogen drugs (such as fulvestrant) to treat patients with HR+/HER2- breast cancer who have already received endocrine therapy but whose disease has progressed. The goal of combination therapy is to enhance the effect of treatment by targeting different therapeutic targets. Apelvis not only prevents tumor cells from taking advantage of proliferation and growth, but also provides additional therapeutic benefits by reducing hormone-dependent cell survival.

However, although Apelvis has achieved significant efficacy in the treatment of breast cancer, its use also has some side effects. Common side effects include high blood sugar, rash, diarrhea, nausea, etc. These side effects are usually caused by the drug's effect on normal cells. In order to reduce the occurrence of side effects, patients need to conduct regular blood glucose monitoring and other related examinations when using Apelvis. In addition, as a targeted therapy drug, Apelvis can only exert its greatest efficacy in patients with PIK3CA gene mutations. Therefore, before treatment, doctors usually confirm whether the patient is suitable for treatment with this drug through genetic testing.

In summary, apelvis exerts an anti-cancer effect by inhibiting the activity of PI3Kα isoform, blocking the PI3K/AKT/mTOR pathway, inhibiting the proliferation and survival of tumor cells. The drug offers an effective treatment option for patients with certain types of breast cancer, but it also requires management of side effects and screening for genetic mutations.

Reference materials:https://www.piqray.com/